 |
|
|
| |
Once-daily alisporivir interferon (IFN)-free regimens achieve high rates of early HCV clearance in previously untreated patients with HCV genotype (G) 2 or 3
|
| |
| |
Reported by Jules Levin
AASLD
Nov 5-9 2011 SF
JM Pawlotsky1, R Flisiak2, J Rasenack3, SK Sarin4, T Piratvisuth5, WL Chuang6, GR Foster7, H Wedemeyer8, C Hezode1, W Zhang9, C Avila10, NV Naoumov10
1Hopital Henri Mondor, Creteil, France; 2Medical University, Biaystok, Poland; 3Albert Ludwigs University, Freiburg, Germany; 4Department of Hepatology, Institute of Liver and Biliary Sciences (ILBS), New Delhi, India; 5NKC Institute of Gastroenterology and Hepatology, Songklanagarind Hospital, Prince of Songkla University, Hat Yai, Thailand; 6Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan; 7Queen Mary, University of London, Bart's and The London School of Medicine, London, UK; 8Department of Gastroenterology, Hepatology and Endocrinology, Medizinische Hochschule Hannover, Hannover, Germany; 9Beijing Novartis Pharma Co. Ltd., Shanghai, China; 10Novartis Pharma AG, Basel, Switzerland
|
| |
|
|
|
|
|
